Moorman Andrew, Benitez Elizabeth K, Cambulli Francesco, Jiang Qingwen, Mahmoud Ahmed, Lumish Melissa, Hartner Saskia, Balkaran Sasha, Bermeo Jonathan, Asawa Simran, Firat Canan, Saxena Asha, Wu Fan, Luthra Anisha, Burdziak Cassandra, Xie Yubin, Sgambati Valeria, Luckett Kathleen, Li Yanyun, Yi Zhifan, Masilionis Ignas, Soares Kevin, Pappou Emmanouil, Yaeger Rona, Kingham T Peter, Jarnagin William, Paty Philip B, Weiser Martin R, Mazutis Linas, D'Angelica Michael, Shia Jinru, Garcia-Aguilar Julio, Nawy Tal, Hollmann Travis J, Chaligné Ronan, Sanchez-Vega Francisco, Sharma Roshan, Pe'er Dana, Ganesh Karuna
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature. 2025 Jan;637(8047):947-954. doi: 10.1038/s41586-024-08150-0. Epub 2024 Oct 30.
As cancers progress, they become increasingly aggressive-metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death. Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance. However, we lack an understanding of metastatic cell states and the mechanisms by which they transition. Here, in a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that, although primary tumours largely adopt LGR5 intestinal stem-like states, metastases display progressive plasticity. Cancer cells lose intestinal cell identities and reprogram into a highly conserved fetal progenitor state before undergoing non-canonical differentiation into divergent squamous and neuroendocrine-like states, a process that is exacerbated in metastasis and by chemotherapy and is associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues compared with their intestinal lineage-restricted primary tumour counterparts. We identify PROX1 as a repressor of non-intestinal lineage in the fetal progenitor state, and show that downregulation of PROX1 licenses non-canonical reprogramming.
随着癌症的进展,它们会变得越来越具有侵袭性——转移性肿瘤对一线治疗的反应比原发性肿瘤更差,它们会对后续治疗产生耐药性,并最终导致死亡。同一患者的原发性肿瘤和转移性肿瘤之间的突变在很大程度上是保守的,这表明非基因表型可塑性在癌症进展和治疗耐药性中起主要作用。然而,我们对转移细胞状态及其转变机制缺乏了解。在此,在一组来自同一患者正常结肠、原发性和转移性结直肠癌的生物样本三联体中,我们表明,虽然原发性肿瘤大多呈现LGR5肠干细胞样状态,但转移灶表现出渐进性可塑性。癌细胞失去肠细胞特征,重编程为高度保守的胎儿祖细胞状态,然后经历非经典分化,形成不同的鳞状和神经内分泌样状态,这一过程在转移过程中以及化疗作用下会加剧,并且与患者的不良生存相关。使用匹配的患者来源类器官,我们证明与肠道谱系受限的原发性肿瘤对应物相比,转移细胞在响应微环境线索时表现出更大的细胞自主多谱系分化潜能。我们确定PROX1是胎儿祖细胞状态下非肠道谱系的抑制因子,并表明PROX1的下调许可非经典重编程。